Cytek Biosciences
CTKB
152 hedge funds and large institutions have $501M invested in Cytek Biosciences in 2024 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 57 increasing their positions, 42 reducing their positions, and 16 closing their positions.
100% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 16
36% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 42
21% more capital invested
Capital invested by funds: $415M → $501M (+$86.1M)
12% more funds holding
Funds holding: 136 → 152 (+16)
2.98% more ownership
Funds ownership: 57% → 59.98% (+3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$3.85M |
| 2 |
Millennium Management
New York
|
+$3.65M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.32M |
| 4 |
JP Morgan Chase
New York
|
+$2.08M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$7.43M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
-$3.18M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.92M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.01M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$729K |
CTKB Hedge Fund Activity: Q4 2024 in Review
152 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q4 2024, worth a combined $501M — up 21% from $415M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new CTKB positions and 16 closed out — a net gain of 16 holders — while 57 added to existing stakes and 42 trimmed.
The largest buyer was UBS Group, adding an estimated $3.85M. The largest seller was Brown Capital Management, cutting an estimated $7.43M.
- 152 institutional investors held Cytek Biosciences (CTKB) as of Q4 2024, up from 136 in Q3 2024.
- Funds reported $501M of Cytek Biosciences stock for Q4 2024, up 21% quarter-over-quarter.
- 32 funds opened new Cytek Biosciences positions in Q4 2024 and 16 closed out, a net change of +16 holders.
- The largest Cytek Biosciences buyer in Q4 2024 was UBS Group, an estimated $3.85M added.
- The largest Cytek Biosciences seller in Q4 2024 was Brown Capital Management, an estimated $7.43M sold.
Based on aggregated 13F filings for Q4 2024.